Navigation Links
Despite Dramatic Changes, the Crohn's Disease Drug Market Will Experience Only Moderate Growth Through 2019

BURLINGTON, Mass., Sept. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the Crohn's disease drug market will experience moderate growth over the next decade, increasing from $3.2 billion in 2009 to $4.2 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This modest growth rate masks dramatic changes as market growth from newer and emerging biologic agents will outpace the decline in sales of older, established agents, which face increasing generics competition and declining use.

The Pharmacor 2010 findings from the topic entitled Crohn's Disease reveal that sales of biologic agents to treat the disease are concentrated as tumor necrosis factor-alpha (TNF-alpha) inhibitors -- namely Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade and Abbott/Eisai's Humira -- dominated the Crohn's disease market in 2009, capturing just over three-quarters of major-market sales. Owing to increasing physician familiarity with these agents and continuing emergence of favorable postmarketing clinical trial data, sales of TNF-alpha inhibitors will continue to grow, reaching approximately $2.8 billion in 2019.

The Pharmacor 2010 findings also reveal that the 2008 U.S. launches of Biogen Idec/Elan's Tysabri (a cell adhesion molecule inhibitor) and UCB/Otsuka's TNF-alpha inhibitor Cimzia had a negligible impact on the Crohn's disease market. Through 2019, both agents will continue to be relegated to second- or later-line biological therapy, behind Remicade and Humira.

"In 2009, sales of maintenance therapies for Crohn's disease greatly exceeded sales of acute therapies," said Decision Resources Analyst Kathryn Benton. "We expect growth in the market will be largely attributable to increasing sales of maintenance therapies and that sales of acute therapies will remain essentially flat through 2019. However, no current therapy is completely effective in maintaining remission of Crohn's disease and, as a result, significant opportunity remains for more-effective emerging therapies in the maintenance space."

Beginning in 2013, several therapies with novel mechanisms of action are expected to launch for Crohn's disease, including Millennium Pharmaceuticals' vedolizumab, Centocor Ortho Biotech/Janssen-Cilag's Stelara, Abbott's briakinumab and ChemoCentryx/GlaxoSmithKline's Traficet-EN.

"However, we forecast that none of these agents will rival the efficacy or the market share of the TNF-alpha inhibitors," Ms. Benton said.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges
2. Despite Economic Turmoil, CIS Named to Inc. 5000 List of Fastest-Growing Private Companies in America
3. Medical Affairs Budget & Staffing Remain Top Challenges Despite Increased Funding
4. UBM Japan Pharma Events Grow Despite Air Travel Disruptions
5. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
6. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
7. Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million
8. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
9. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
10. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
11. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):